Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 90 citing articles:

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Bo Xu, Shaoqian Li, Bo-Kyeong Kang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 116
Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
Alison K. Wright, Matthew Carr, Evangelos Kontopantelis, et al.
Diabetes Care (2022) Vol. 45, Iss. 4, pp. 909-918
Open Access | Times Cited: 96
Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study
Che‐Yuan Wu, Carina Iskander, Christa Wang, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. 297-304
Open Access | Times Cited: 76
Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels
Elvira D’Andrea, Deborah J. Wexler, Seoyoung C. Kim, et al.
JAMA Internal Medicine (2023) Vol. 183, Iss. 3, pp. 242-242
Open Access | Times Cited: 54
Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments
Sebastian Schneeweiß, Elisabetta Patorno
Endocrine Reviews (2021) Vol. 42, Iss. 5, pp. 658-690
Open Access | Times Cited: 86
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Melanie J. Davies, Heinz Drexel, François R. Jornayvaz, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 44
Metformin and Cancer: Solutions to a Real-World Evidence Failure
Oriana Hoi Yun Yu, Samy Suissa
Diabetes Care (2023) Vol. 46, Iss. 5, pp. 904-912
Open Access | Times Cited: 35
Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study
Han Eol Jeong, Sohee Park, Yunha Noh, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 23
Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation
Akash Fichadiya, Amity E. Quinn, Flora Au, et al.
EP Europace (2024) Vol. 26, Iss. 3
Open Access | Times Cited: 14
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
Adam J. Nelson, Neha J. Pagidipati, Vanita R. Aroda, et al.
Circulation (2021) Vol. 144, Iss. 1, pp. 74-84
Open Access | Times Cited: 55
Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus
Arash Aghajani Nargesi, Gini Priyadharshini Jeyashanmugaraja, Nihar R. Desai, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 13
Open Access | Times Cited: 53
SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 172, pp. 105836-105836
Open Access | Times Cited: 46
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
Yan Xie, Benjamin Bowe, Andrew K. Gibson, et al.
JAMA Internal Medicine (2021) Vol. 181, Iss. 8, pp. 1043-1043
Open Access | Times Cited: 43
Brachial-ankle pulse wave velocity and prognosis in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis
Tiantian Sang, Naqiang Lv, Aimin Dang, et al.
Hypertension Research (2021) Vol. 44, Iss. 9, pp. 1175-1185
Closed Access | Times Cited: 41
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
Advances in secondary prevention mechanisms of macrovascular complications in type 2 diabetes mellitus patients: a comprehensive review
Huifang Guan, Jiaxing Tian, Ying Wang, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 7
Association between subjective physical function and occurrence of new fractures in older adults: A retrospective cohort study
So Sato, Yusuke Sasabuchi, Shotaro Aso, et al.
Geriatrics and gerontology international/Geriatrics & gerontology international (2024) Vol. 24, Iss. 4, pp. 337-343
Open Access | Times Cited: 6
Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
Hiroki Akiyama, Akihiro Nishimura, Naru Morita, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 14
SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
Xiaodan Wang, Jingyu Ni, Rui Guo, et al.
Heart Failure Reviews (2021) Vol. 27, Iss. 3, pp. 961-980
Closed Access | Times Cited: 31
Methodological challenges using routine clinical care data for real-world evidence: a rapid review utilizing a systematic literature search and focus group discussion
Michelle Pfaffenlehner, Max Behrens, Daniela Zöller, et al.
BMC Medical Research Methodology (2025) Vol. 25, Iss. 1
Open Access
Impact of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on Cardiovascular Events in Type 2 Diabetes
Hamza Shabbir, Muhammad Rasikh, Khalid Bashir, et al.
Indus journal of bioscience research. (2025) Vol. 3, Iss. 1, pp. 320-324
Closed Access
Diabetes and stroke: An important complication
Zachary T. Bloomgarden, Robert Ćhilton
Journal of Diabetes (2020) Vol. 13, Iss. 3, pp. 184-190
Open Access | Times Cited: 29
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care
Iskandar Idris, Ruiqi Zhang, Jil Billy Mamza, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 10, pp. 2207-2214
Open Access | Times Cited: 25
Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review
Chun‐Ting Yang, Zi‐Yang Peng, Yi‐Chi Chen, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top